Last Updated : October 17, 2024
Details
Generic Name:
datopotamab deruxtecan
Project Status:
Pending
Therapeutic Area:
advanced or metastatic non-squamousnon-small cell lung cancer (NSCLC)
Manufacturer:
AstraZeneca Canada Inc.
Call for patient/clinician input open:
Brand Name:
TBC
Project Line:
Reimbursement Review
Project Number:
PC0384-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the treatment of adult patients with locally
advanced or metastatic non-squamous non-small cell lung cancer (NSCLC)
who have received platinum doublet chemotherapy,
in the advanced or metastatic setting and at least one additional therapy, either in combination or sequentially.
Fee Schedule:
Pending
Indications:
For the treatment of adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) who require systemic therapy following prior treatment:
• Patients without known actionable genomic alterations previously treated with platinum-based chemotherapy in the advanced or metastatic setting and programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) inhibitor, either in combination or sequentially;
• Patients with actionable genomic alterations previously treated with prior platinum-based therapy and targeted therapy for the detected alteration.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Last Updated : October 17, 2024